A comparative controlled trial of intralesionally-administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis.
A comparative clinical trial between two newly introduced intralesional treatments for acute leishmaniasis and the established treatment of intralesionally-administered pentavalent antimony compounds was performed. Treatments were allocated randomly to a total of 63 patients who received 2% zinc sulphate, 7% sodium chloride solutions or sodium stibogluconate intralesionally. A number of patients were left without treatment as controls. Patients were followed-up for 45 days, the results showing that the three treatments gave comparable cure rates by the end of the follow-up period. However, zinc sulphate gave a high cure rate (94.8%) usually with a single injection.
Sharquie
K E
KE
Department of Dermatology, College of Medicine, University of Baghdad, Iraq.
Najim
R A
RA
Farjou
I B
IB
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012965:Sodium Chloride / Q000008:administration & dosage; D016896:Treatment Outcome; D019287:Zinc Sulfate / Q000008:administration & dosage
D000981:Antiprotozoal Agents; D012965:Sodium Chloride; D019287:Zinc Sulfate; D000967:Antimony Sodium Gluconate